Download poster

Download Full Text (900 KB)


Higher rates of COVID-19 related hospitalization and death are reported in patients with underlying health conditions and advanced age as compared to the general population.While polyclonal immunity generated by vaccines has demonstrated protection against severe disease, vaccine response takes time and may be inadequate in some high-risk populations.1 Treatment with anti-SARS-CoV-2 neutralizing monoclonal antibodies affords prompt, passive humoral immunity and has been shown in randomized, controlled trials to reduce rates of hospitalization and death from COVID-19 in high-risk ambulatory patients treated early in the course of infection.2,3 The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization for four monoclonal antibody products requiring intravenous administration including bamlanivimab monotherapy (since retracted), casirivimab/imdevimab, bamlanivimab/etesevimab (since retracted) and sotrovimab for the treatment of early, mild-moderate COVID-19 in high-risk outpatients as well as inpatients not hospitalized for COVID-19. How to effectively identify qualifying patients, arrange for infusion and administer therapy, however, poses challenges to the widespread, equitable utilization of these potentially lifesaving therapies.

Publication Date



COVID-19, monoclonal antibodies, anti-viral therapy


Infectious Disease | Medicine and Health Sciences


Presented at ID Week 2021: the annual meeting of the Infectious Diseases Society of America

Anti-SARS-CoV-2 Monoclonal Antibodies for Early COVID-19: A Real-World Experience